In vitro insulinomimetic activities of Zn(II) complexes with three natural products, betaine, L-lactic acid, and D-(؊)-quinic acid (qui), were found in rat adipocytes treated with epinephrine in terms of the inhibition of free fatty acid release. Based on the results, the blood glucose lowering effect in KK-A y mice with type 2 diabetes mellitus was observed by daily i.p. injections of a monomeric zinc(II) complex, Zn(qui) 2 , for 13 d.
Diabetes mellitus (DM) is a disease associated with absolute or relative insulin deficiency. Several types of medicines for the treatment of non-insulin-dependent type 2 DM have been developed all over the world. However, such therapeutic medicines have some problems involving side effects. 1) In 1980, Coulston and Dandona reported the first insulinomimetic activity 2) of Zn(II) ion, which is one of the essential trace elements and exists in more than 300 metalloproteins and active sites of various metalloenzymes.
3) Following this finding, several research groups attempted to confirm the insulinomimetic activity of Zn(II) ion. [4] [5] [6] For example, Shisheva et al. reported that Zn(II) stimulates glucose uptake and lipid synthesis in rat adipocytes and oral administration of a high dose of ZnCl 2 (210 mg/kg body weight) to STZ-induced model diabetic rats with insulin-dependent type 1 diabetes reduces the blood glucose concentration as much as 50%. 5) On the other hand, Chen et al. found the hypoglycemic effect of ZnCl 2 (20 mM) in type 2 diabetic ob/ob mice. 6) However, Zn(II) complexes have never been examined.
It was reported that bis(maltolato)Zn(II) complex, Zn(Mal) 2 , increases the absorption in erythrocytes more than free Zn(II) ion. 7) Recently, we found that Zn(Mal) 2 with a Zn(O 4 ) coordination mode has a higher insulinomimetic activity than free Zn(II) ions as estimated in in vitro experiments. 8) In addition, we have reported that Zn(II) complexes with Zn(O 4 ), Zn(N 2 O 2 ), Zn(N 2 S 2 ), Zn(O 2 S 2 ), and Zn(S 4 ) coordination modes have high insulinomimetic activities with regard to in vitro experiments and blood glucose lowering effects. [9] [10] [11] [12] [13] [14] [15] [16] [17] In this paper, we report the insulinomimetic activities of Zn(II) complexes with natural products (betaine (bet), L-lactic acid (lac), and D-(Ϫ)-quinic acid (qui)) with a Zn(O n ) coordination mode and the blood glucose lowering effects of Zn(lac) 2 2 ] n in aqueous solution were determined by using a vapor pressure osmometer, according to the method described previously. 20, 21) Urea was used as a standard compound to calibrate the apparatus. A complex, Zn(bet) 3 4 , 24 mM NaHCO 3 , 5 mM glucose: pH 7.4) containing 2% BSA (Sigma Chemical Co.). A 10 Ϫ5 M epinephrine was then added to the incubation mixtures and the resulting solutions were incubated at 37°C for 180 min. The reaction was stopped by soaking in ice water and the mixture was centrifuged at 3000 rpm for 10 min. For the outer solutions of the cells, FFA levels were determined with an FFA kit (Wako Pure Chemicals).
Blood Glucose It is known that urea is one of the most suitable compounds as a standard solute when a vapor pressure osmometer is utilized in an aqueous solution, because urea is neither a dissociable nor an associable compound at relatively low concentration ranges in aqueous solution. Namely, urea exists as a monomeric species in aqueous solution. In general, the average dissociation number, n, can be defined as: nϭ(DE value of the complex)/(DE value of urea) at a given concentration of the solute. The resulted n values were nϭ2.65, 0.47, and 0.92 for Zn(bet) 3 (ClO 4 ) 2 , Zn(lac) 2 , and Zn(qui) 2 2 In vitro insulinomimetic activities of three Zn(II) complexes were estimated by inhibition of the release of FFA from isolated rat adipocytes treated with epinephrine, 17) and were confirmed to be dose-dependent in the concentration range of 0.1-1 mM of the complex. The apparent IC 50 values, a 50% inhibitory concentration of the FFA release, of the three complexes exhibited insulinomimetic activities comparable with those of VOSO 4 and ZnSO 4 as shown in Table 1 2 (IC 50 ϭ0.81 and 0.98, respectively), were used in this test because they had the top 2 of insulinomimetic activities as shown in Table 1 . As shown in Fig. 1 , the body weights didn't decrease in all groups. The food intake decreased temporarily when Zn(II) complexes with lactic and quinic acids were administered, but the food intake recovered for two days after their administrations. The drinking water intake didn't change in all groups.
When [Zn(lac) 2 ] 2 and Zn(qui) 2 complexes were injected daily at a dose of 3 mg (45.9 mmol) Zn/kg of body weight of mice for 13 d, the blood glucose level of the animals given Zn(qui) 2 was lowered to approximately 200 mg/dl (11.1 mM) (Fig. 2) . The blood glucose level of the animals given [Zn(lac) 2 ] 2 was also lowered, but the fall ratio was low compared with that of Zn(qui) 2 .
HbA 1c and Serum Parameters The levels of HbA 1c , which shows the number of glucose molecules attached to the hemoglobin in the erythrocytes over a long period, were measured. In KK-A y mice untreated and treated with [Zn(lac) 2 ] 2 , the HbA 1c levels increased from 8.0Ϯ1.1 to 8.6Ϯ1.0 (%) and 6.5Ϯ1.1 to 6.9Ϯ1.0 (%) before and after the administration, respectively. In contrast, the HbA 1c level of the KK-A y mice treated with Zn(qui) 2 decreased from 8.1Ϯ1.1 to 5.7Ϯ1.7 (%) before and after the administration, respectively. The result suggested that the blood glucose lowering effect of Zn(qui) 2 complex continued for a long-term.
After KK-A y mice were administered the complex for 13 d and fasted for 14 h on the final administration day, all parameters were measured. GOT, GPT, BUN, TG, TCHO, and FFA levels in the control KK-A y mice (untreated) and KK-A y mice treated with Zn(qui) 2 complex for 13 d were summarized in Table 2 .
No serum parameters changed compared with those of the control KK-A y mice. In short, the administration of Zn(qui) 2 complex by daily i.p. injections exhibited no renal and hepatic disturbances, indicating that Zn(II) complex with a natural product is safe for KK-A y mice. In conclusion, the present study revealed that daily i.p. injections of a monomeric complex, Zn(qui) 2 , lowered the blood glucose level in KK-A y mice with type 2 diabetes mellitus. Moreover, the dimeric complex, [Zn(lac) 2 ] 2 , showed a blood glucose lowering effect, however, it was weak. On the bases of the results, we proposed here that the monomeric complex in aqueous solution is a better antidiabetic agent than the dimeric complex.
The result on Zn(qui) 2 shows not only the importance of Zn(II) monomeric complex with a low toxic natural product in treating experimental diabetic mellitus but also the possibility to develop a new clinically useful and low toxic Zn(II) complex. 
